REPORT #09-002
                                           Capitalizing on New Opportunities...
Overview (continued)                                                         Methodology
lines. But while the excitement a...
Report Highlights
Capitalizing on New Opportunities for Stem Cell Products
REPORT #09-002

Report Highlights (continued)
Capitalizing on New Opportunities for Stem Cell Products
REPORT #09-002

Other Recent Publications*
Life Science Marketing

About BioInformatics, LLC                                                    Our strength lies in our ability to integrate...
REPORT #09-002                                                                                             ...
Upcoming SlideShare
Loading in …5

Capitalizing on New Opportunities for Stem Cell Products


Published on

"Capitalizing on New Opportunities for Stem Cell Products" was designed to provide estimates on market share, projected growth of the stem cell research products market, types and species of stem cells scientists intend to use, suppliers – and level of satisfaction with – stem cell media, unmet product needs and more. Beyond providing an understanding of the current stem cell products market, this report will help identify the new/expanding stem cell research opportunities as a result of the change in the current administration’s policies regarding human embryonic stem cells research.

Published in: Health & Medicine, Technology
1 Like
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Capitalizing on New Opportunities for Stem Cell Products

  1. 1. EXECUTIVE SUMMARY REPORT #09-002 Capitalizing on New Opportunities Overview April 2009 for Stem Cell Products Print: $3,200 $2,700 Electronic (.pdf): $5,200 $4,500 This pre-publication discount price is only available until May 17, 2009! Overview & Key Findings Methodology of products purchased from each major supplier), and plan As a result of the March 9, 2009 reversal of the 2001 restrictions a long-term strategy to secure your leading position in this on federal funding of human embryonic stem cell research, expanding market. For tactical planning purposes, the report suppliers of stem cell related products are in need of a fast, includes detailed market share estimates across major stem cell accurate assessment of new opportunities in the stem cell product categories by market segment, geographic region and top products market. Additionally, given that practical stem cell- suppliers. Combined with data on scientists’ stem cell research based therapies can take years to develop, suppliers will benefit budgets and expected changes in spending through 2011, from a clear understanding of the wide range of products that suppliers can use this information to anticipate areas of growth support basic stem cell research already in progress. Capitalizing and product saturation. on New Opportunities for Stem Cell Products, BioInformatics LLC’s latest report, will enable suppliers to respond quickly to Report Highlights One key finding in this report was that only 14% of the scientists a market disrupted by an Executive Order, and to gain a better surveyed indicated that the lifting of the restrictions on federal understanding of how today’s stem cell products market is funding for human embryonic stem cell research will affect their driven by long-term stem cell research requirements. decision as to what types of stem cells Contact us at to use in their research; the majority In Capitalizing on New Opportunities for Stem Cell Products, 703.778.3080 x13 of study will still involve using adult we surveyed close to 500 scientists from around the world stem cells, suggesting that these about their current—and planned—areas of research, usage of to review the study cells will continue to play a major stem cell products and preferred suppliers. This report will help questionnaire role in advancing the field of stem you to determine areas poised for growth (i.e., media, sera, cell research. Furthermore, almost supplements and cell lines) in the stem cell research products half of the scientists indicated that the goal of their research market, identify potential key competitors (including percentage Analyst Expertise is understanding basic biology of stem cells, as opposed to developing cell-based therapies, drug discovery or preclinical/ Report Objectives clinical trials. More specifically, we have found that 75% of respondents are focused on stem cell differentiation, which has tremendous implications for product development. (Please see • Identify new/expanding stem cell research opportunities page 2 for supporting data.) as a result of the ban on federal funding for research on human embryonic stem cells being lifted This analysis also provides suppliers with critical insight into optimizing product offerings based upon scientists’ level of • Estimate market share and project growth of stem cell satisfaction with stem cell culture products and the level of research products by market segment and geographic Company Information interest in developing integrated stem cell product lines and region services. The scientists surveyed share their opinions on what • Estimate market share of top suppliers by stem cell new product/technologies would be most beneficial to their research product category (i.e., media, sera, supplements, research. Additionally, the report reveals what channels stem cell and cells) scientists use to access information relevant to their research, which in turn can be used by suppliers to more effectively target • Learn types and species of stem cells scientists intend their products and services. to use • Determine level of satisfaction with stem cell media and The March 2009 policy change will have implications for life unmet needs with respect to stem cell products and cell science suppliers as academic scientists consider conducting lines research on previously unavailable human embryonic stem cell BioInformatics • Anticipate change in spending on stem cell products and Order Form cell lines over the next two to three years (through 2011) market insights from gene to drug 2111 Wilson Blvd • Project market size for stem cell products through 2011 Suite 250 • Uncover interest in integrated stem cell workflow products Arlington, VA 22201 and services www.gene2drug.com 703.778.3081 (fax) Capitalizing on New Opportunities for Stem Cell Products Executive Summary Page 1 of 7 ©2009 BioInformatics, LLC
  2. 2. Overview (continued) Methodology lines. But while the excitement about human embryonic stem Capitalizing on New Opportunities for Stem Cell cell research is on the rise, including in the pharmaceutical and Products is based on responses to a 60-question Overview biotech industry, suppliers need actionable information about online survey conducted by BioInformatics, LLC. scientists’ plans to pursue research using all types of cell lines in The questionnaire was completed by nearly 500 life a global market. This report provides insights into the origins and scientists worldwide who currently perform stem sources of stem cells currently used in the lab (adult, embryonic cell research or plan to perform stem cell research and induced pluripotent) and those likely to be used over the between March 23 and April 6, 2009. The questionnaire next several years—in addition to differentiated cell types and consisted of 39 closed or partially close-ended associated diseases under investigation—allowing suppliers to questions and 21 open-ended questions designed to anticipate the types of stem cell culture products scientists will encourage participation and to meet objectives of the need to purchase. Moreover, this report includes a supplemental study. section about scientists who plan to conduct stem cell research & Key Findings Methodology in the near future to help companies better anticipate the stem The questions were answered by highly-qualified cell product needs of new customers. members of The Science Advisory Board™. BioInformatics sponsors The Science Advisory Capitalizing on New Opportunities for Stem Cell Products Board™, an online community of more than 43,000 provides a roadmap for stem cell product suppliers to help scientists engaged in basic biological research, clinical navigate a landscape that is poised for change—and growth. This research and drug discovery and development. These analysis was designed to guide suppliers in redirecting resources experts have agreed to make themselves available to new areas and markets, and to help refine current offerings to answer questions including emerging areas of by making them more responsive to scientists who are already research, the tools and techniques used in their labs, engaged in stem cell research. and their satisfaction with their current suppliers. Report Highlights Key Findings Theme That Best Reflects The Goal of Their Research Feature(s) of Stem Cells Studied/Employed Employing stem 75% Differentiation cells in preclinical/ clinical trials 41% Pluripotency marker(s) 8% Analyst Expertise 37% Self-renewal Developing cell- based therapies Understanding 37% Propagation using stem cells the basic biology 23% of stem cells 45% 30% Drug screening toxicity Reprogramming 26% Using stem cells 23% Epigenetics in drug discovery and/or Company Information development 4% Other 24% Is Your Decision as to What Types of Stem Cells to Use Affected by the Embryonic stem cells in Lifting of the US Restrictions on Federal Funding for Human Embryonic place of adult stem cells and/or induced Stem Cell Research? pluripotent stem cells No 8% 56% Yes, because I will Embryonic stem cells in 47% 14% now study... addition to adult stem 45% cells and/or induced Order Form pluripotent stem cells 13% 17% Additional embryonic stem cell lines Don't know/ Not not sure applicable Capitalizing on New Opportunities for Stem Cell Products Executive Summary Page 2 of 7 ©2009 BioInformatics, LLC
  3. 3. Report Highlights Capitalizing on New Opportunities for Stem Cell Products REPORT #09-002 Overview Section 1. Analysis • Source and type of stem cell lines plan to use two to three years from now (2010 and 2011) Market Size and Share and Market Growth Potential • Impact on research of lifting US restrictions on federal • Estimated market share for stem cell research products funding of embryonic stem cells by market segment and geographic region • Differentiated cell types that were/are/will be the focus • Estimated market share of top suppliers by stem of stem cell research for 2008, 2009, and two to three cell research product category (i.e., media, sera, years from now (2010 and 2011) supplements, and cells) & Key Findings Methodology • Diseases that are the focus of stem cell research by type • Projected growth of stem cell research products market of stem cell by market segment and geographic region • Top scientific journals respondents rate as most critical • Anticipated stem cell research budgets for 2009 by to their stem cell research market segment and geographic region • Critical stem cell conferences • Expected change in spending on stem cell products and cell lines over the next two to three years (through 2011) Stem Cell Culture Products: Top Suppliers and Budgets • Suppliers from whom respondents purchase stem cell culture products Report Highlights Frequently Asked Questions (related to): • Percent of stem cell culture product purchases made • Products needed to support scientists’ current stem cell from leading suppliers research • Estimated 2008 budget for stem cell culture products • Cell types and disease that are/will be the focus of stem cell research • Percent of 2008 budget spent on stem cell media, sera, and supplements • Use of embryonic versus induced pluripotent cells for specific applications • Estimated 2009 budget that will be dedicated to stem cell culture products and stem cell lines • Unmet product needs and product differentiation strategies • Percent of 2009 budget that will be spent on stem cell Analyst Expertise media, sera, and supplements • New product and/or service development opportunities • Expected change in expenditures on stem cell media, • Best channels by which to communicate with and sera, and supplements over the next two to three years market to stem cell researchers (2010 and 2011) Stem Cell Media: Usage, Product Features and Special Section 2. Methodology & Demographics Requirements • Objectives • Types of media used to grow and culture stem cells • Questionnaire design • Percent of media that is custom vs. off-the-shelf Company Information • Survey population • Estimate of stem cell culture media used per month in 2008 • Estimate of stem cell culture media expected to be used per month in 2009 Section 3. Presentation of the Survey Data: • Expected change in stem cell culture media usage for Respondents Conducting Stem Cell Research two to three years from now (2010 and 2011) Research Overview and Applications • Importance of xeno-free and animal-free types of stem • Length of time conducting research cell culture media • Goals of stem cell research • Advantages of stem cell culture media from primary supplier • Features of stem cells studied Order Form • Satisfaction with features of stem cell culture media from • Source, type, and number of different stem cell lines primary supplier used in 2008 • Requirements for GMP conditions for stem cell culture • Source, type, and number of different stem cell lines products expected to be used in 2009 Capitalizing on New Opportunities for Stem Cell Products Executive Summary Page 3 of 7 ©2009 BioInformatics, LLC
  4. 4. Report Highlights (continued) Capitalizing on New Opportunities for Stem Cell Products REPORT #09-002 Overview Stem Cells: Sources, Budgets, and Special Requirements Additional Analysis by: hoose Why C port? • General sources from which respondents acquire • Market segment e This R stem cells • Geographic region ) 5 age • Percent of stem cell purchases made from major sources (see p • Years of experience in 2008 • Stem cell type • Percent of stem cell purchases expected to be made from • Research focus major sources in 2009 & Key Findings Methodology • Lab size • Expected changes in the percent of stem cell purchases expected to be made from commercial suppliers over the next two to three years (2010 and 2011) • Commercial suppliers and/or national bank/repositories Section 4. Appendices from which respondents currently purchase stem cells Appendix A. Respondents Planning to Conduct Stem Cell • Percent of stem cell purchases made from commercial Research suppliers and/or national bank/repositories • Time frame that respondents plan to begin stem cell • Estimated 2008 budget for stem cell lines research • Estimated 2009 budget that will be dedicated to stem cell Report Highlights • Sources of funding that will support future stem cell lines research • Reasons why respondents acquire stem cells from their • Anticipated annual budget for stem cell culture products primary suppliers and stem cell lines • Percent of stem cells grown on feeders and sources of • Sources and types of stem cells respondents plan to use feeder cells in their research • Use of 3-D cell culture in stem cell research • Differentiated cell types that will be the focus of stem • Reasons for interest in 3-D cell culture for stem cell cell research research • Diseases that will be the focus of stem cell research by Analyst Expertise cell type Supporting Products, Technologies, and Services • Sources from which respondents plan to acquire stem cells • Techniques respondents use to identify differentiated cell types derived from stem cells • Major disadvantages of techniques used to identify Appendix B. Verbatim Responses to Questions differentiated cell types derived from stem cells • Do you think your stem cell research will change due • Primary supplier of consumable products used to to the lifting of US restrictions on federal funding perform techniques for identifying differentiated cell for human embryonic stem cell research by the new types derived from stem cells presidential administration? Why or why not? Company Information • Stem cell-specific kits or panels currently used and • Like many stem cell pioneers, Ian Wilmut, the creator of planned to use in the next 12 months Dolly the sheep, has embraced an alternative approach. Are induced pluripotent stem cells the beginning of the • Stages of stem cell workflow processes with which end for embryonic cloning? Why or why not? respondents are involved • Stage of stem cell workflow that respondents would most like a new product/technology to facilitate their research • Types of stem cell-related services that respondents would be most interested in obtaining from suppliers . Order Form Capitalizing on New Opportunities for Stem Cell Products Executive Summary Page 4 of 7 ©2009 BioInformatics, LLC
  5. 5. Other Recent Publications* Life Science Marketing Overview #09-001 Prospering in a Down Market: Strategies for Life Science Suppliers March 2009 159 Pages #08-047 The Brave New World of Scientific Publishing November 2008 154 Pages #08-019 Enabling Discovery: The 2008 Life Science Industry Awards June 2008 101 Pages TM #08-008 Instrumentation Service Contracts: Opportunities for Differentiation July 2008 136 Pages #08-007 Protein Research: Strategies for Marketing to Chemists and Biologists September 2008 123 Pages #08-006 Understanding Switching Dynamics: Maximizing Customer Retention in the Life Science March 2008 173 Pages #08-004 Life Science Product Catalogs: Techniques to Increase Sales March 2008 92 Pages & Key Findings Methodology #08-003 Conference & Exhibit Strategies in the Life Sciences: What’s Working Now February 2008 135 Pages #08-002 Advertising to Life Scientists: Resolving the Print vs. Online Dilemma February 2008 105 Pages #08-001 Marketing to Life Scientists: Capturing Customers’ Attention in Applied Markets January 2008 156 Pages * See Web site www.gene2drug.com for a complete listing. With hundreds of stem cell products market reports to choose from, why choose ours? Report Highlights The design and analysis of Capitalizing on Carefully Selected Survey Participants New Opportunities for Stem Cell Products When others promote results from their online surveys, they fail to mention the uncontrolled nature of their was spearheaded by BioInformatics LLC’s Vice broadcast email invitations. To provide you with the most President of Advisory Services Tamara Zemlo, valid and accurate results possible, the respondents to our Ph.D., MPH, who has been the lead analyst on surveys are members of our unique online panel—The over 80 syndicated market research reports. For Science Advisory Board—which consists of more than this study, Dr. Zemlo consulted with multiple 43,000 verified life science and biomedical professionals stem cell products vendors to optimize the Analyst Expertise who have agreed to take part in our surveys, focus groups relevance of this study with regards to the and other market research activities. These respondents current stem cell research market. are carefully selected based on their professional qualifications, market segments and geographic regions—we can even select them based on the products Sources of Independent, Unbiased Research they use and their preferred suppliers. Unlike reports from other firms that are based on an analyst’s subjective summary of information from publicly available sources, our reports are based on the results Don’t settle for an imitation. Invest in the most of detailed surveys of hundreds—even thousands—of direct source of information from the scientists scientific and medical professionals who buy your Company Information who buy your products, and the expert team that products. has been monitoring your clients since 1994. Developed by a Team of Experts Complimentary Consulting Provided Our questionnaires are developed by a multi- disciplinary team of scientists, industry veterans and With your purchase, we offer one free hour of consultation market research experts with years of experience. These with our talented team of scientific and business analysts professionals understand that survey questions need to who created the report. During this consultation, we can be asked in a way that ensures the answers will directly answer any questions you may have about the survey address the business challenges you face. Once the survey results and what we believe to be the significant trends data is collected, this same team creates a unique report affecting the market. that presents the reader with a thorough understanding of Custom Analysis & Research Available the topic and the scientific and business implications of Order Form the results based on sophisticated statistical analytics. If you’d like to delve deeper into the data from a study, we can always perform custom cross-tabulations or other analysis on your behalf. We can even pose follow-up questions to respondents who answered in a particular way or conduct a custom study to extend your knowledge. Capitalizing on New Opportunities for Stem Cell Products Executive Summary Page 5 of 7 ©2009 BioInformatics, LLC
  6. 6. About BioInformatics, LLC Our strength lies in our ability to integrate our understanding of science and medicine with cutting-edge market research techniques. As one of the first firms to recognize how the World Wide Web has Since our inception in 1994, BioInformatics has provided critical transformed market research, BioInformatics formed The Science market intelligence to leading companies serving the life science, medical device and pharmaceutical industries. We support clients Advisory Board. Launched in 1997, this global community currently Overview across the entire market spectrum—from scientific research to consists of more than 43,000 life science researchers, physicians diagnostics and therapeutics—providing high-level management with and biomedical professionals who convene regularly via the Web to market insights from gene to drug. voice their opinions on a wide variety of issues relating to biomedical research and clinical technologies. Clients tap into this panel of Our multi-disciplinary team of scientific experts and business experts and receive answers to their critical marketing questions in analysts creates value for our clients by combining extensive industry days, rather than weeks. In addition to providing real-time insights knowledge and experience. We offer a variety of products and into the perceptions of the market, posing questions to The Science services that enable executives to see themselves, their market and Advisory Board offers substantial cost savings over gathering their competitors through the eyes of the most important information information via traditional market research techniques. source of all—customers. We can precisely meet the needs of our & Key Findings Methodology clients through the most appropriate mix of research methodologies, BioInformatics offers both published reports and custom research including: services. Published reports allow marketing professionals to share in • Online Surveys the results of broad-based market studies that provide access to high • Online Focus Groups quality research at an affordable price. Our custom research is tailored • Mail Surveys to the specific needs of the company’s executive management. For • Telephone Interviews more information about BioInformatics’ product and service offerings, please visit our Web site at www.gene2drug.com, call 703.778.3080 or email info@gene2drug.com. Our Valued Clients Report Highlights Biotechnology/Life Science Eppendorf Plexagen Diagnostics Ortho-Clinical Diagnostics Phillip Johnson & Associates 454 Eurogentec Post Genome Institute Radiometer America PA Consulting AbCam Expression Pathology Promega Tektronix Perry Ballard Accelrys Fermentas Protein Forest Piper Jaffray Pharmaceuticals Affymetrix Fluidigm Proteome Systems Ruder Finn Agencourt Bioscience GE Healthcare Qbiogene Abbott Laboratories Scherago International Agilent Technologies Gen-Probe QIAGEN Amgen Select Equity Group American Type Culture Gene Codes R & D Systems AstraZeneca Stephan & Brady Collection Gene Logic Ribomed Biotechnologies Aventis The Strategy Works Anachem Gene Therapy Systems Rosetta Biosoftware Baxter Healthcare UBS Warburg Antibodies By Design Gentra Systems Sachem Bayer Apple Computer Publishers & Associations GenVault Corporation Sarstedt Boehringer Ingelheim Applied Biosystems Pharmaceuticals Genzyme Sandia National Laboratories Academic Press Analyst Expertise Applied Precision Cardinal Health Guava Technologies SAS Institute American Academy of Axxora Centocor Pediatrics Helicos BioSciences Schott Nexterion BD Biosciences Hoechst Marion Roussel AAAS/Science Hewlett-Packard Sequenom Beckman Coulter ICN Pharmaceuticals American Medical Association High Throughput Genomics Serologicals Biacore Janssen Pharmaceutica American Society for Cell Hitachi Instruments Serotec Biology Bio-Rad Laboratories Merck Hybrigenics Sigma-Aldrich American Society for Bioneer Novartis Pharmaceuticals Hyseq Solexa Microbiology Biotage Novo Nordisk IBM Life Sciences SomaLogic American Society of Human Pharmaceuticals BioTrove Illumina Source Precision Medicine Genetics Pfizer Blue Heron Biotechnology Immunotech Stratagene BioTechniques/Eaton Schering-Plough Caliper Technologies InforMax Stressgen Biotechnologies Publishing Callida Genomics Integrated DNA Technologies Takara Mirus Bio Blackwell Publishing Company Information Professional Services Cambrex Bio Science Invitrogen Tecan Cold Spring Harbor & Finance Carl Zeiss JRH Biosciences The Jackson Laboratory Laboratory Press Adjuvant Partners Cell Signaling Technology Kirkegaard & Perry Thermo Fisher Scientific Elsevier Adventus Research Celliance Laboratories Thomas Scientific Federation of Amer. Societies Agency.com Charles River Laboratories Kodak Scientific Imaging Tocris Cookson for Experimental Biology Anvil Group ChromaVision Medical Leica Microsystems Transgenomic Harvard University Medical Atlas Venture Systems LI-COR UVP School Battelle Memorial Institute Cipher Systems LION bioscience Varian John Wiley & Sons BioOnline Clontech Laboratories Lonza VWR International Mary Ann Liebert Publishers Citadel Investment Group Corning Luminex Vysis Nature Publishing Group Doran Media Services DAKO MDS Sciex Waters New England Journal of Fidelity Management and DNAStar Mettler-Toledo AutoChem Whatman Medicine Research Dow Corning Millipore Society for Neuroscience Foley & Lardner Dynal Biotech MiraiBio Medical Diagnostics Springer-Verlag Gerson Lehrman Group eBIOINFORMATICS Molecular Devices Applied Imaging Stanford University High Wire HSBC Securities Edge Biosystems MWG Biotech Ciba Corning Diagnostics Order Form Press Infotrieve Eksigent Technologies New England Biolabs Dade Behring Thomson ISI Innovative Marketing Group EM Separations Technology NuGEN Technologies Diagnostic Products Wolters Kluwer McKinsey & Co. EMD Biosciences Ovid Technologies Diametrics Medical Nathan Associates Entelechon Pall Life Sciences Hewlett-Packard Medical National Research Council of Epigenomics Percival Scientific Products Canada Epitomics PerkinElmer Life Sciences LifeScan Novintel Epoch Biosciences Photometrics Mallinckrodt Capitalizing on New Opportunities for Stem Cell Products Executive Summary Page 6 of 7 ©2009 BioInformatics, LLC
  7. 7. BioInformatics REPORT #09-002 market insights from gene to drug Capitalizing on New Opportunities for Stem Cell Products Overview PRE-PUBLICATION DISCOUNT PRICES are only available until May 17, 2009! Print Copy—$3,200 Now $2,700! Electronic Copy (includes one print copy)—$5,200 Now $4,500! Ordering Information Electronic Copy To place an order, fill out this form and mail it to BioInformatics, LLC or fax This format allows an unlimited number of users within your company it to 703.778.3081. Alternatively, you may submit your order by emailing to access the report regardless of geographic location. You may place the sales@gene2drug.com, calling 703.778.3080 or visiting electronic copy (PDF) on your secure, corporate intranet or share it with & Key Findings Methodology www.gene2drug.com/order/201/. co-workers via email. In addition to providing greater accessibility, the electronic copy allows you to easily navigate the document with the help Payment must be made within 30 days and in U.S. dollars. of bookmarks, quickly search key words or phrases and print out any page. BioInformatics’ Federal Tax ID #: 54-2001907. One print copy of the report is also provided at no additional cost. Credit Card Data Set You may charge your order to American Express, MasterCard, Visa, To accommodate your unique needs, the raw data is also available. With Diner’s Card or Discover. Please include your credit card account number, the data, you can analyze respondents’ answer choices in any way needed, expiration date and signature. including cross-tabulations, correlations, etc. The data set is offered in two formats: SPSS® Base or Microsoft® Excel, and may only be purchased in Wire Transfers conjunction with the company-wide electronic copy of the report. Wire transfers should be sent to: SunTrust Bank, 2121 15th Street, Arlington, Report Highlights VA 22201, SWIFT #SNTRUS3A, ABA #071000104, Account #702260169. I wish to order the following format of REPORT #09-002, Capitalizing on New Opportunities for Stem Cell Products Discount Price o Print Copy $2,700 $________ o Electronic Copy (.pdf, includes print copy) $4,500 $________ o Add Data Set Excel or SPSS (circle one) +$1,200 +$________ Additional print copies _____ x $300 each +$________ Analyst Expertise Promo Code ___________ –$________ Shipping & Handling +$________ (Add $15 for U.S., $50 for Int’l) $________ Total o Check Enclosed (Payable to BioInformatics, LLC) Company Information o Purchase Order # ________________________________________ Name o Bill Me Title o Am Ex o MasterCard o Visa o Diner’s Card o Discover Organization  / Street Address Credit Card # Exp Date (MM/YY) City, State/Province, Postal Code Name on card _____________________________________________ Country Order Authorized By: Order Form Phone Fax __________________________________________________________ Signature Date Email BioInformatics, LLC 2111 Wilson Blvd., Suite 250 Arlington, VA 22201 Web: www.gene2drug.com • Phone: 703.778.3080 x13 • Fax: 703.778.3081 • Email: m.follin@gene2drug.com Capitalizing on New Opportunities for Stem Cell Products Executive Summary Page 7 of 7 ©2009 BioInformatics, LLC